SEARCH

SEARCH BY CITATION

References

  • Becker, P.B., and Wu, C. (1992). Cell-free system for assembly of transcriptionally repressed chromatin from Drosophila embryos. Mol. Cell. Biol. 12, 22412249.
  • Boehm, N., Samama, B., Cribier, B., and Rochette-Egly, C. (2004). Retinoic acid receptor beta expression in melanocytes. Eur. J. Dermatol. 14, 1923.
  • Brtko, J., and Thalhamer, J. (2003). Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr. Pharm. Des. 9, 20672077.
  • Chakravarti, N., Lotan, R., Diwan, A.H., Warneke, C.L., Johnson, N.M., and Prieto, V.G. (2007). Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin. Cancer Res. 13, 48174824.
  • Cras, A., Darsin-Bettinger, D., Balitrand, N., Cassinat, B., Soulie, A., Toubert, M.E., Delva, L., and Chomienne, C. (2007). Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid resistant thyroid cancer cells. Oncogene 26, 40184024.
  • De Ambrosis, A., Ferrari, H., Bonassi, G., and Vidali, G. (1987). Nucleosomal repeat length in active and inactive genes. FEBS Lett. 225, 120122.
  • Demary, K., Wong, L., and Spanjaard, R.A. (2001). Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett. 163, 103107.
  • Fang, M.Z., Chen, D., Sun, Y., Jin, Z., Christman, J.K., and Yang, C.S. (2005). Reversal of hypermethylation and reactivation of p16INK4a, RARbeta and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11, 70337041.
  • Fields, A.L., Soprano, D.R., and Soprano, K.J. (2007). Retinoids in biological control and cancer. J. Cell. Biochem. 102, 886898.
  • Fligiel, S.E., Inman, D.R., Talwar, H.S., Fisher, G.J., Voorhees, J.J., and Varani, J. (1992). Modulation of growth in normal and malignant melanocytic cells by all-trans retinoic acid. J. Cutan. Pathol. 19, 2733.
  • Germain, P., Chambon, P., Eichele, G., Evans, R.M., Lazar, M.A., Leid, M., De Lera, A.R., Lotan, R., Mangelsdorf, D.J., and Gronenmeyer, H. (2006). Retinoid X Receptors. Pharmacol. Rev. (International Union of Pharmacology) 58, 760772.
  • Goodman, D.S. (1984). Vitamin A and retinoids in health and disease. N. Engl. J. Med. 310, 10231031.
  • Hocker, T.L., Singh, M.K., and Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol. 128, 25752595.
  • Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293, 10741080.
  • John, S., Sabo, P.J., Johnson, T.A. et al. (2008). Interaction of the glucocorticoid receptor with the chromatin landscape. Mol. Cell 29, 611624.
  • Kato, Y., Salumbides, B.C., Wang, X.F., Qian, D.Z., Williams, S., Wei, Y., Sanni, T.B., Atadja, P., and Pili, R. (2007). Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis retinoic acid in human malignant melanoma. Mol. Cancer Ther. 6, 7081.
  • Liu, Z., Zhang, L., Ding, F. et al. (2005). 5-Aza-2′-deoxycytiidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett. 230, 271283.
  • Liu, S., Ren, S., Howell, P., Fodstad, O., and Riker, A.I. (2008). Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 21, 545558.
  • Lotan, R. (1996). Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. 16, 24152419.
  • Ma, X., Exxeldin, H.H., and Diasio, R.B. (2009). Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 19111934.
  • Munshi, A., Shafi, G., Aliya, N., and Jyothy, A. (2009). Histone modifications dictate specific biological readouts. J. Genet. Genomics 36, 7588.
  • Niles, R.M. (2002). The use of retinoids in the prevention and treatment of skin cancer. Expert Opin. Pharmacother. 3, 299303.
  • Pavan, B., Biondi, C., and Dalpiaz, A. (2006). Nuclear retinoic acid receptor beta as a tool in chemoprevention trials. Curr. Med. Chem. 13, 35533563.
  • Recchia, F., Candeloro, G., Necozione, S., Fumagalli, L., Bratta, M., and Rea, S. (2008). Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. Anticancer Drugs 19, 201207.
  • Rodríguez-Campos, A., Shimamura, A., and Worcel, A. (1989). Assembly and properties of chromatin containing histone H1. J. Mol. Biol. 209, 135150.
  • Sabichi, A.L., Hendricks, D.T., Bober, M.A., and Birrer, J.F. (1998). RAR-beta expression and growth inhibition of gynecological cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J. Natl. Cancer Inst. 90, 597605.
  • Shaw, R.J., Liloglou, T., Rogers, S.N., Brown, J.S., Vaughan, E.D., Lowe, D., Field, J.K., and Risk, J.M. (2006). Promoter methylation of p16, RAR beta, E-cadherin, cyclin A1, and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J. Cancer 94, 561568.
  • Shen, S., Kruyt, F.A., Den Hertoq, J., Van Der Saag, P.T., and Kruijer, W. (1991). Mouse and human RAR beta 2 promoters: sequence comparison and localization of retinoic acid responsiveness. DNA Seq. 21, 111119.
  • Soengas, M.L., and Lowe, S.W. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 31383151.
  • Suh, Y.A., Lee, H.Y., Virmani, A., Wang, J., Mann, K.K., Miller Jr, W.H., Gazdar, A., and Kurie, J.M. (2002). Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. 62, 39453949.
  • Sun, S.Y. (2004). Retinoic acid receptor beta and colon cancer. Cancer Biol. Ther. 3, 8788.
  • Virmani, A.K., Rathi, A., Zochbauer-Muller, S. et al. (2001). Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92, 13031307.
  • Widschwendter, M., Berger, J., Muller, H.M., Zeimet, A.G., and Marth, C. (2001). Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J. Mammary Gland Biol. Neoplasia 6, 193201.
  • Wolffe, A.P., and Matzke, M.A. (1999). Epigenetics: regulation through repression. Science 286, 481486.
  • Xu, X.C. (2007). Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 253, 1424.
  • Yang, Q., Shan, L., Yoshimura, G., Nakamura, M., Nakamura, Y., Suzuma, T., Umemura, T., Mori, I., Sakurai, T., and Kakudo, K. (2002). 5-aza-2′-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res. 22, 27532756.
  • Zhuang, Y., Faria, T.N., Chambon, P., and Gudas, L.J. (2003). Identification and characterization of RAR-beta2 target genes in F9 teratocarcinoma cells. Mol. Cancer Res. 1, 619630.